Work

P334 Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme

Year: 2021

Type: conference-abstract

Source: Journal of Crohn s and Colitis

DOI: 10.1093/ecco-jcc/jjab076.458

Authors: R C Ungaro, M A Ciorba, G Rogler, A I Sharara, N Sunna, S B Connelly, R Mundayat, N Lawendy, J Panés

Institutions: Icahn School of Medicine at Mount Sinai, Washington University in St. Louis, University of Zurich, American University of Beirut Medical Center, Pfizer (United States), Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3167796082

Cites:

Cited by:

Related to: 10